

CLINICAL TRIAL SUMMARY DESCRIPTION

TITLE: Thalidomide and Temozolomide in Treating Young Patients with Relapsed or Progressive Brain Tumors or Recurrent Neuroblastoma

OBJECTIVE OF STUDY: To determine the effectiveness of combining thalidomide with temozolomide in treating young patients

MINIMUM ELIGIBILITY REQUIREMENTS: Patients 21 years of age and under

PARTICIPANT ACTIVITIES (*office visits, tests, take medications, etc*): Participants will receive oral temozolomide for 5 days and oral thalidomide for 28 days, every 28 days for 6 courses.

CONTACT INFORMATION: **COORDINATOR** / **CHAIR** (*please circle one*)

NAME/TITLE: Dr. Mark Kieran

AFFILIATION: Dana-Farber Cancer Institute

MAILING ADDRESS: Boston, MA USA

PHONE: 617.632.4907

Email ADDRESS:

WEBSITE (*for complete info*): <http://www.clinicaltrials.gov/ct/show/NCT00098865?order=6>